Inquiry Basket
Loading ......
Filter By Product Search for
ACMSD
ACMSD Full Name
aminocarboxymuconate semialdehyde decarboxylase
ACMSD Introduction
Aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a critical zinc-dependent amidohydrolase that plays a pivotal "gatekeeping" role in the kynurenine pathway of tryptophan metabolism. Located primarily in the liver, kidneys, and central nervous system, ACMSD dictates the ultimate metabolic fate of its unstable substrate, alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS). The fundamental physiological function of ACMSD is to catalyze the decarboxylation of ACMS into alpha-aminomuconate semialdehyde (AMS), which is subsequently channeled toward complete oxidation via the citric acid cycle or converted into the neuroprotective metabolite, picolinic acid. Crucially, when ACMSD activity is low or its substrate is overabundant, ACMS non-enzymatically cyclizes into quinolinic acid (QUIN). While a baseline level of QUIN is necessary for the de novo biosynthesis of nicotinamide adenine dinucleotide (NAD+), excessive QUIN acts as a potent endogenous neurotoxin and an agonist of the NMDA receptor. Therefore, ACMSD is essential for tightly maintaining the balance between neurotoxic QUIN accumulation, neuroprotective picolinic acid, and systemic NAD+ homeostasis.
Figure 1. Overview of the kynurenine pathway of tryptophan metabolism. (Source: Jones SP, et al. 2013)
Clinically, the dysregulation of ACMSD is profoundly implicated in a spectrum of neurodegenerative and neuroinflammatory diseases. Because quinolinic acid induces severe excitotoxicity and triggers microglia-mediated inflammation, impaired ACMSD activity directly contributes to neuronal death. Recently, specific genetic mutations and rare variants in the ACMSD gene have been identified in patients with Parkinson's disease (PD), cortical myoclonus, and epilepsy. In these neurodegenerative states, the loss of ACMSD function leads to the toxic accumulation of QUIN in the brain. Conversely, ACMSD is also emerging as a highly attractive therapeutic target in the field of metabolic diseases and aging. Because inhibiting ACMSD artificially forces the metabolic pathway toward QUIN and subsequently boosts intracellular NAD+ levels, pharmacological ACMSD inhibitors are currently being developed to treat NAD+-depleted conditions, such as acute kidney injury, mitochondrial disorders, and type 2 diabetes. Thus, ACMSD represents a fascinating metabolic node where its natural activation protects against neurodegeneration, while its targeted pharmacological inhibition offers potential systemic metabolic benefits.
Alternate Names for ACMSD
ACMSD; aminocarboxymuconate semialdehyde decarboxylase; 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase; picolinate carboxylase;
Loading ......
